BTK and B-cell chronic lymphocytic leukemia: Selinexor is currently in a phase 1 trial in combination with the BTK inhibitor (BTKi) ibrutinib for patients with relapsed/refractory CLL or aggressive non-Hodgkin lymphoma (NCT02303392) [10].